The original disclosure in Japanese was released on Nov. 9, 2023 at 15:30 (GMT+9)
Consolidated Financial Statements for the Second Quarter Ended September 30, 2023 FY2024 (April 1, 2023 - March 31, 2024) [UNAUDITED]
Company name: | Takara Holdings Inc. | |
Stock exchange listings: | Tokyo Stock Exchange (PRIME section) | |
Code number: | 2531 | |
URL: | https://www.takara.co.jp/ | |
Company representative: | Mutsumi Kimura, President | |
Contact: | Masakazu Usami, General Manager of Public Relations& Investor Relations Dept. | |
TEL:(075)241-5124 | ||
Quarterly statement filing date(as planned): | November 13, 2023 |
Notes: | 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted |
in Japan. |
2. Amounts are rounded down to the nearest million yen.
1. Results for the six months ended September 30, 2023 (April 1, 2023 - September 30, 2023)
- Consolidated operating results
Note: Percentages indicated changes from the same period of the previous fiscal year. | |||||||||||||
Six months ended | Six months ended | ||||||||||||
September 30, 2023 | September 30, 2022 | ||||||||||||
(Millions of yen) | (%) | (Millions of yen) | (%) | ||||||||||
Net sales | 163,172 | (0.7) | 164,279 | 16.3 | |||||||||
Operating income (loss) | 12,464 | (36.5) | 19,614 | (9.3) | |||||||||
Ordinary income (loss) | 13,032 | (34.7) | 19,972 | (8.7) | |||||||||
Net income (loss) attributable to owners of the parent | 8,043 | (26.0) | 10,873 | 8.2 | |||||||||
Net income (loss) per share (Yen) | 40.69 | 55.00 | |||||||||||
Fully diluted net income per share (Yen) | - | - | |||||||||||
Note: Comprehensive income (loss) | 26,272 | (13.0) | 30,213 | 43.5 | |||||||||
(2) Consolidated financial position | |||||||||||||
As of September 30, 2023 | As of March 31, 2023 | ||||||||||||
(Millions of yen) | (Millions of yen) | ||||||||||||
Total assets | 420,865 | 399,174 | |||||||||||
Net assets | 272,071 | 255,318 | |||||||||||
Equity ratio (%) | 52.2 | 51.1 | |||||||||||
(Reference) Equity | 219,688 | 203,951 | |||||||||||
2. Dividends | |||||||||||||
Dividend per share (Yen) | |||||||||||||
Year ended March 31, | Year ending March 31, | Year ending March 31, | |||||||||||
2023 | 2024 | 2024 (Forecast) | |||||||||||
First quarter end | - | - | - | ||||||||||
Second quarter end | - | - | - | ||||||||||
Third quarter end | - | - | - | ||||||||||
Year end | 38.00 | - | 27.00 | ||||||||||
Annual | 38.00 | - | 27.00 |
Note: Correction of dividend forecast from the most recent dividend forecast: No
3. Forecast for the year ending March 31, 2024 (April 1, 2023 - March 31, 2024)
Note: Percentages indicated changes from the same period of the previous fiscal year.
Year ending March 31, 2024
(Millions of yen) | (%) | |
Net sales | 341,000 | (2.8) |
Operating income (loss) | 21,700 | (42.8) |
Ordinary income (loss) | 22,500 | (41.9) |
Net income (loss) attributable to owners of the parent | 15,000 | (29.3) |
Net income per share (Yen) | 75.87 | |
Note: Correction of financial forecast from the most recent financial forecast: Yes |
4. Others
- Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No
- Accounting procedures specific to quarterly consolidated financial statements : No
- Changes in accounting policies, accounting estimates and retrospective restatement
- Changes based on revisions of accounting standard: No
- Changes other than ones based on revisions of accounting standard: No
- Changes in accounting estimates: No
- Restatement: No
- Number of outstanding shares (common stock)
- Number of outstanding shares at the end of each period (Treasury stocks are included):
As of September 30, 2023 : | 199,699,743 shares | ||
As of March 31, 2023 : | 199,699,743 shares | ||
2) | Number of treasury stocks at the end of each period: | ||
As of September 30, 2023 : | 1,995,673 shares | ||
As of March 31, 2023 : | 1,995,612 shares | ||
3) | Average number of outstanding shares in each period | ||
Six months ended September 30, 2023 | : | 197,704,122 shares | |
Six months ended September 30, 2022 | : | 197,704,145 shares |
Contents of the attached document
1. Qualitative Information for the Six Months Ended September 30, 2023 …………………………………………..…… | 2 |
(1) Consolidated Financial Results ……………………………………………………………………….……………… | 2 |
(2) Consolidated Financial Position ……………………………………………………………………………………… | 3 |
(3) Qualitative Information Regarding Consolidated Forecasts …………………………………..……………………… | 4 |
2. Consolidated Quarterly Financial Statements and Primary Notes ………………………………………………………… | 6 |
(1) Consolidated Balance Sheets ……………………………………………………………………….………………… | 6 |
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ……………………… | 8 |
(Consolidated Statements of Income) …………………………………………………………………………..…… | 8 |
(For the Six Months Ended September 30, 2023 and 2022) | |
(Consolidated Statements of Comprehensive Income) ……………………………………………………………… | 9 |
(For the Six Months Ended September 30, 2023 and 2022) | |
(3) Consolidated Statements of Cash Flows…………………………………………………………….………………… | 10 |
(4) Notes to Consolidated Financial Statements …………………………………………………………….…………… | 11 |
(Notes on Premise of Going Concern) ……………………………………………………………………………… | 11 |
(Notes on Material Changes in Shareholders' Equity) ……………………………………………………………… | 11 |
(Segment Information) ……………………………………………………………………………………………… | 11 |
(Significant Subsequent Events) | 12 |
○ Supplement for the Consolidated Quarterly Financial Statements |
- 1 -
1. Qualitative Information for the Six Months Ended September 30, 2023
- Consolidated Financial Results
In the six months ended September 30, 2023, net sales decreased 0.7% year on year to ¥163,172 million, gross profit decreased 4.2% year on year to ¥55,459 million, and SG&A expenses increased 12.4% year on year to ¥42,995 million. Operating income decreased 36.5% year on year to ¥12,464 million, ordinary income decreased 34.7% year on year to ¥13,032 million, and net income attributable to owners of the parent decreased 26.0% year on year to ¥8,043 million.
Results by business segment were as follows.
[Takara Shuzo]
In the six months ended September 30, 2023, although sales of light-alcohol refreshers and raw alcohol increased year on year, shochu, sake, and Hon Mirin decreased.
As a result, net sales for Takara Shuzo decreased 1.0% year on year to ¥61,190 million. Cost of sales decreased 5.3% year on year to ¥45,216 million, mainly due to a change in the sales mix, despite the continued impact of rising raw material prices. Gross profit increased 13.6% year on year to ¥15,974 million. SG&A expenses were in line with the equivalent period of the previous fiscal year, increasing 0.2% year on year to ¥12,021 million. Operating income was up 91.9% year on year to ¥3,952 million.
[Takara Shuzo International Group]
In the six months ended September 30, 2023, net sales of the Overseas Alcoholic Beverages Business increased year on year mainly due to continued growth in sales of whiskey in the U.S. and U.K. as well as an increase in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased as the eating and drinking establishment market continued to perform well, with the development of new business bases also contributing positively.
As a result, net sales for the Takara Shuzo International Group increased 21.1% year on year to ¥77,164 million. Cost of sales increased 20.7% year on year to ¥52,786 million in line with the increase in net sales. Consequently, gross profit increased 22.0% year on year to ¥24,377 million. SG&A expenses were up 26.5% year on year to ¥18,120 million, primarily due to an increase in personnel expenses and transportation costs, and operating income was up 10.6% year on year to ¥6,256 million.
[Takara Bio Group]
In the six months ended September 30, 2023, sales of testing-related reagents decreased due to changes in the legal categorization of COVID-19. As a result, net sales for the Takara Bio Group decreased 41.3% year on year to ¥19,116 million. Cost of sales decreased 45.3% year on year to ¥5,772 million, mainly due to a decrease in net sales. Consequently, gross profit decreased 39.4% year on year to ¥13,343 million. SG&A expenses were up 7.0% year on year to ¥11,933 million, primarily due to increases in personnel expenses and R&D expenses. Operating income decreased 87.0% year on year to ¥1,410 million.
[Other]
In the six months ended September 30, 2023, net sales of the Other segment decreased 4.6% year on year to ¥14,866 million due to decreased sales in the transportation business and the printing business. Cost of sales decreased 5.0% year on year to ¥12,729 million. Consequently, gross profit decreased 2.2% year on year to ¥2,136 million. SG&A expenses increased 0.2% year on year to ¥943 million, and operating income was down 4.0% year on year to ¥1,193 million.
- 2 -
Breakdown of sales results by product category
Equivalent Period of | Period under Review | |||
Previous Fiscal Year | YoY | |||
Segment | (From April 1, 2023, | |||
(From April 1, 2022, | Comparison | |||
to September 30, 2023) | ||||
to September 30, 2022) | ||||
Product category | Amount (Millions of yen) | Amount (Millions of yen) | (%) | |
Takara Shuzo | ||||
Shochu | 19,998 | 17,469 | (12.6) | |
Sake | 4,697 | 4,252 | (9.5) | |
Light-alcohol refreshers | 20,525 | 21,782 | 6.1 | |
Other alcoholic beverages | 2,823 | 2,750 | (2.6) | |
Hon Mirin | 4,710 | 4,546 | (3.5) | |
Other seasonings | 4,321 | 4,447 | 2.9 | |
Raw alcohol, etc. | 4,743 | 5,941 | 25.2 | |
Total | 61,820 | 61,190 | (1.0) | |
Takara Shuzo International Group | ||||
Overseas Alcoholic | 8,287 | 10,262 | 23.8 | |
Beverages Business | ||||
Japanese Food | ||||
Wholesales Business in | 56,421 | 68,084 | 20.7 | |
overseas markets | ||||
Other | 2,812 | 215 | (92.4) | |
Elimination of intra-Group | (3,791) | (1,397) | - | |
transaction on consolidation | ||||
Total | 63,730 | 77,164 | 21.1 | |
Takara Bio Group | ||||
Reagents | 27,565 | 14,949 | (45.8) | |
Instruments | 694 | 411 | (40.7) | |
CDMO | 3,183 | 2,702 | (15.1) | |
Gene therapy | 1,144 | 1,052 | (8.0) | |
Total | 32,587 | 19,116 | (41.3) | |
Reported segment total | 158,138 | 157,471 | (0.4) | |
Other | 15,577 | 14,866 | (4.6) | |
Segment total | 173,715 | 172,338 | (0.8) | |
Sales not allocated to | ||||
business segments and | (9,435) | (9,165) | - | |
intersegment transactions | ||||
Total | 164,279 | 163,172 | (0.7) | |
Note: 1. Amounts include alcohol tax. |
(2) Consolidated Financial Position
As of September 30, 2023, current assets were ¥240,349 million, a decrease of ¥1,164 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥7,453 million, despite increases in notes and accounts receivable-trade and merchandise and finished goods of ¥1,646 million and ¥3,189 million, respectively.
Noncurrent assets were ¥180,516 million, an increase of ¥22,855 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥11,856 million, mainly due to increases in buildings and structures and construction in progress, intangible assets of ¥1,048 million, and investments and other assets of ¥9,950 million due to an increase in the market valuation of investment securities.
As a result, total assets were ¥420,865 million, an increase of ¥21,691 million compared with that at the end of the previous fiscal year.
As of September 30, 2023, current liabilities were ¥76,847 million, an increase of ¥9,392 million compared with that at the end of the previous fiscal year. This was primarily due to increases in short-term loans payable of ¥5,160 million, current portion of bonds of ¥5,000 million, and accrued alcohol tax of ¥3,458, despite a decrease in other under current liabilities of
- 3 -
¥4,698 million due to decreases in accrued payments. Noncurrent liabilities were ¥71,946 million, a decrease of ¥4,454 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in bonds payable of ¥5,000 million and long-term loans payable of ¥4,703 million, despite an increase in other under noncurrent liabilities of ¥5,303 million.
As a result, total liabilities were ¥148,794 million, an increase of ¥4,938 million compared with that at the end of the previous fiscal year.
As of September 30, 2023, total net assets were ¥272,071 million, an increase of ¥16,753 million compared with that at the end of the previous fiscal year. This was primarily due to increases in valuation difference on available-for-sale securities of ¥4,688 million and foreign currency translation adjustment of ¥10,416 million due to the ongoing weakening of the yen.
As a result, the equity ratio totaled 52.2%, compared with 51.1% at the end of the previous fiscal year.
In the six months ended September 30, 2023, net cash provided by operating activities increased ¥7,691 million year on year to ¥14,922 million primarily due to income before income taxes of ¥12,984 million, depreciation and amortization of ¥4,796 million, an increase in accrued alcohol tax of ¥3,458 million, a decrease in other current liabilities of ¥2,453 million, and ¥3,319 million in income taxes paid.
Net cash used in investing activities resulted in expenditure of ¥15,796 million, an increase in expenditure of ¥6,243 million compared to the same period of the previous fiscal year primarily due to purchase of property, plant and equipment and intangible assets of ¥14,540 million.
Net cash used in financing activities resulted in expenditure of ¥9,711 million, a decrease in expenditure of ¥11,913 million compared to the same period of the previous fiscal year primarily due to cash dividends paid of ¥7,497 million.
As a result, cash and cash equivalents as of September 30, 2023, including effect of exchange rate change on cash and cash equivalents, stood at ¥84,446 million, down ¥7,339 million from the previous fiscal year-end.
(3) Qualitative Information Regarding Consolidated Forecasts
The Company has revised the full-year consolidated results forecasts published on May 11, 2023 in consideration of recent performance trends.
With regard to the outlook for each segment for the full year ending March 31, 2024, we expect to fall short of our previous forecast owing to lower than expected sales volumes of Hon Mirin, raw alcohol, etc., for Takara Shuzo. With regard to operating income, although net sales will not meet our targets, we expect to exceed our previous forecast owing to efforts to decrease our SG&A expenses in spite of improvements we have made in terms of advertising expenses which we have achieved through efforts to keep a lid on rising costs and through efficient use of sales promotion expenses.
With regard to the Takara Shuzo International Group, we expect that net sales will fall short of our previous forecast owing to an ongoing slowdown of consumer spending in response to inflation. We also expect operating income to fall short of our previous forecasts owing to a predicted failure to meet our targets for gross profit as a result of a drop in net sales.
With regard to net sales of the Takara Bio Group, we expect that sales from the business for reagents and instruments and the CDMO business (genetic analysis) will fall short of our previous forecast owing to a slump in the global life sciences R&D market in response to prolonged inflation and an economic downturn and because of increased price competition for products and services. We also expect operating income to fall short of our previous forecasts owing to a predicted failure to meet our targets for gross profit as a result of a drop in net sales.
As a result of the above, net sales, operating income, and ordinary income are all expected to fall short of our previous forecasts. We have not made any changes to our previous forecast for net income attributable to owners of the parent as extraordinary income will be recorded due to sales of cross-shareholdings. The details of the consolidated results forecasts and the results forecasts for each segment are described on pages 10/15-13/15 in "Supplement for the Consolidated Financial Statements."
Note: Today (November 9, 2023), the Company subsidiary Takara Bio Inc. (listed on the Prime Market of the Tokyo Stock Exchange with securities code number 4974) also revised its consolidated results forecasts for the full-year consolidated results forecast ending March 31, 2024, published in the financial statements on May 11, 2023.
- 4 -
(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2024)
Net income | |||||
Net sales | Operating income | Ordinary income | attributable to | Net income per | |
owners of the | share | ||||
parent | |||||
Previous forecast (A) | (Millions of yen) | (Millions of yen) | (Millions of yen) | (Millions of yen) | (Yen) |
355,000 | 26,300 | 26,800 | 15,000 | 75.87 | |
(Published May 11, 2023) | |||||
Revised forecast (B) | 341,000 | 21,700 | 22,500 | 15,000 | 75.87 |
Difference (B - A) | (14,000) | (4,600) | (4,300) | - | - |
Difference (%) | (3.9) | (17.5) | (16.0) | - | - |
Reference:Business | |||||
results for previous fiscal | 350,665 | 37,945 | 38,706 | 21,206 | 107.26 |
year (Ended March 31, | |||||
2023) | |||||
- 5 -
2. Consolidated Quarterly Financial Statements and Primary Notes
- Consolidated Balance Sheets
(Millions of Yen) | ||
As of Mar. 31, 2023 | As of Sept. 30, 2023 | |
Assets | ||
Current assets | ||
Cash and deposits | 96,820 | 89,367 |
Notes and accounts receivable-trade | 69,717 | 71,363 |
Merchandise and finished goods | 57,812 | 61,002 |
Work in process | 1,718 | 2,132 |
Raw materials and supplies | 7,372 | 7,577 |
Other | 8,765 | 9,589 |
Allowance for doubtful accounts | (694) | (684) |
Total current assets | 241,513 | 240,349 |
Noncurrent assets | ||
Property, plant and equipment | 88,890 | 100,747 |
Intangible assets | ||
Goodwill | 10,668 | 11,505 |
Other | 5,262 | 5,474 |
Total intangible assets | 15,931 | 16,980 |
Investments and other assets | ||
Investment securities | 30,573 | 37,373 |
Other | 22,328 | 25,478 |
Allowance for doubtful accounts | (64) | (63) |
Total investments and other assets | 52,838 | 62,789 |
Total noncurrent assets | 157,661 | 180,516 |
Total assets | 399,174 | 420,865 |
- 6 -
(Millions of Yen) | ||
As of Mar. 31, 2023 | As of Sept. 30, 2023 | |
Liabilities | ||
Current liabilities | ||
Notes and accounts payable-trade | 21,775 | 22,126 |
Short-term loans payable | 4,919 | 10,079 |
Current portion of bonds | - | 5,000 |
Accrued alcohol tax | 5,815 | 9,274 |
Accrued expenses | 6,368 | 6,019 |
Income taxes payable | 2,220 | 2,824 |
Provision | 3,622 | 3,488 |
Other | 22,733 | 18,035 |
Total current liabilities | 67,454 | 76,847 |
Noncurrent liabilities | ||
Bonds payable | 20,000 | 15,000 |
Long-term loans payable | 15,186 | 10,482 |
Net defined benefit liability | 8,925 | 8,872 |
Other | 32,288 | 37,591 |
Total noncurrent liabilities | 76,401 | 71,946 |
Total liabilities | 143,856 | 148,794 |
Net assets | ||
Shareholders' equity | ||
Capital stock | 13,226 | 13,226 |
Capital surplus | 1,994 | 1,994 |
Retained earnings | 163,825 | 164,356 |
Treasury stock | (1,682) | (1,682) |
Total shareholders' equity | 177,363 | 177,893 |
Accumulated other comprehensive income | ||
Valuation difference on available-for-sale securities | 12,974 | 17,663 |
Deferred gains or losses on hedges | 286 | 290 |
Foreign currency translation adjustment | 13,686 | 24,103 |
Remeasurements of defined benefit plans | (359) | (261) |
Total accumulated other comprehensive income | 26,588 | 41,795 |
Noncontrolling interests | 51,366 | 52,382 |
Total net assets | 255,318 | 272,071 |
Total liabilities and net assets | 399,174 | 420,865 |
- 7 -
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)
(For the Six Months Ended September 30, 2023 and 2022)
(Millions of Yen) | ||
FY2022 | FY2023 | |
(Apr. 1, 2022 - | (Apr. 1, 2023 - | |
Sept. 30, 2022) | Sept. 30, 2023) | |
Net sales | 164,279 | 163,172 |
Cost of sales | 106,400 | 107,713 |
Gross profit | 57,879 | 55,459 |
Selling, general and administrative expenses | 38,264 | 42,995 |
Operating income | 19,614 | 12,464 |
Nonoperating income | ||
Dividends income | 445 | 496 |
Other | 452 | 551 |
Total nonoperating income | 898 | 1,048 |
Nonoperating expenses | ||
Interest expenses | 149 | 184 |
Share of loss of entities accounted for using equity | 113 | - |
method | ||
Foreign exchange losses | 113 | - |
Provision for loss on litigation | - | 109 |
Other | 163 | 185 |
Total nonoperating expenses | 539 | 480 |
Ordinary income | 19,972 | 13,032 |
Extraordinary income | ||
Gain on sale of noncurrent assets | 252 | 28 |
Gain on sale of investment securities | - | 8 |
Insurance claim income | 652 | - |
National subsidies | 63 | - |
Total extraordinary income | 967 | 36 |
Extraordinary loss | ||
Loss on sale and retirement of noncurrent assets | 45 | 84 |
Loss on tax purpose reduction entry of noncurrent | 63 | - |
assets | ||
Other | 16 | - |
Total extraordinary losses | 125 | 84 |
Income before income taxes | 20,815 | 12,984 |
Income taxes-current | 5,405 | 4,290 |
Income taxes-deferred | 580 | (337) |
Total income taxes | 5,985 | 3,953 |
Net income | 14,829 | 9,031 |
Net income attributable to the noncontrolling interest | 3,956 | 988 |
Net income attributable to owners of the parent | 10,873 | 8,043 |
- 8 -
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Takara Holdings Inc. published this content on 28 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2023 08:11:16 UTC.